JPRN-UMIN000026009CompletedPhase 1
Exploratory trial of a combination therapy of mFolfirinox and immunotherapy against pancreatic cancer. - Exploratory trial of a combination therapy of mFolfirinox and immunotherapy against pancreatic cancer.
Department of Gastroenterology and Hepatology, School of Medicine, Kochi University0 sites1 target enrollmentStarted: February 6, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 1
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Patients with uncontrollable infectious diseases (including active Tuberculosis) 2) patients with severe complications (malignant lypertension, severe congestive heart failure, severe colonary in sufficiency, myocardial, infarction within three months, terminal, stage of liver cirrhousis, uncontrollable diabetes mellitus, severe pulmonary fibrosis, active interstitial pneumonitis, etc.) 3) patients with serious comorbidities (generally those of NCI-CTC ver 3.0 grade 3 or higher) 4) patients who have been under parenteral nutrition for more than 24 hours due to impairment of digestive organs. 5) liver metastasis occupying more than 1/3 of the liver 6) Patients with active concomitant malignancy 7) patients with hematopoietic malignancies including MDS, MDS/MPD, CML 8) patients who have received bone marrow or hematopoietic stem cell transplantation 9) Pregnant or breast-feeding women 10)Patients with severe psychiatric diseases 11)Inappropriate patients for this study judged by the physicians.
Investigators
Similar Trials
Unknown
Phase 3
Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.Type 2 diabetesJPRN-jRCT2080220136KISSEI PHARMACEUTICAL CO.,LTD.
Active, not recruiting
Not Applicable
Phase II trial to evaluate the combination of FOLFOX6 + Bevacizumab in initially unresectable liver metastases from colorectal cancerMETASTHATIC COLON-RECTUM AND KIDNEY CANCERMedDRA version: 9.1Level: LLTClassification code 10055114Term: Colon cancer metastaticEUCTR2005-002269-35-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
Completed
Phase 1
Phase I/II Study of Combination Therapy of Oral Fluorinated Pyrimidine Compound S-1 with Low-dose Cisplatin in Patients with Unresectable and/or Recurrent Advanced Gastric Cancer Step 2: low dose cisplatin given twice a week + S-1unresectable or recurrent gastric cancerJPRN-C000000282Japanese Foundation for Multidisciplinary Treatment of Cancer52
Recruiting
Phase 2
A phase II trial of combination therapy with palonosetron / dexamethasone or palonosetron / aprepitant / dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients with urothelial cancer.JPRN-UMIN000010460Yokohama city university80
Not yet recruiting
Phase 1
In Hindi-Manas Mandata Ki Chikitsa Me Medhya Rasayan Ka PrabhavIn English-To Study The Effect Of Combination Of Medhya Rasayana In I.Q.Deficit childreCTRI/2020/05/025368Shri Narayan Prasad Awasthi Government Ayurved College Raipur Chhattisgarh